Lavipharm announced today the signing of a strategic commercial agreement with the multinational pharmaceutical company iNova Pharmaceuticals, owner of, among others, the renowned brand Betadine.

The agreement covers the rights to commercialize a new Lavipharm antiseptic drug from iNova in 60 countries, the company said in a statement, adding: "This is an over-the-counter (OTC) pharmaceutical formulation, developed by Lavipharm's research laboratories in Greece, has already received marketing approval from the first European competent authorities, and sales are expected to start in the last quarter of the year. Lavipharm will produce the product at its facility in Peania for the majority of international markets, while at the same time proceeding with its launch in Greece. 

Lavipharm CEO, Telemachos Lavidas, said: "2025 begins with another sealing of our strategy for business growth and strengthening our international presence. We are particularly proud that iNova is partnering with Lavipharm in implementing its strategy to breathe new life into the Betadine brand by including one of our products in its international portfolio. Looking to the future, we continue to invest in innovation, meet the needs of patients worldwide, and create value for our shareholders."

On behalf of iNova Pharmaceuticals, the company's CEO, Dan Spira, commented: "We are excited to strengthen our relationship with Lavipharm, a trusted manufacturer and distributor of Betadine® products in Greece for many years. We are already preparing for the launch in international markets of the new non-prescription drug developed by Lavipharm at the end of this year. This is an exciting time for iNova Pharmaceuticals as we expand into new product categories and geographies following the acquisition of the flagship Betadine brand in 2024."